FDA Brief

Warning letters Drugs

FDA warning letter to

Ningbo Poplar Daily-Use

High riskIssued Feb 5, 2024Posted Feb 13, 2024Center for Drug Evaluation and Research | CDER

FDA warned Ningbo Poplar Daily-Use that its OTC drugs had manufacturing quality failures in testing, component identity checks, and stability data.

What happened

FDA reviewed records the company submitted after FDA's June 10 and June 24, 2022 requests under a records-request provision (section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act); this was a records review, not an inspection. FDA found the firm did not test finished OTC drug batches for identity and strength before release, did not test incoming component identity, and used a hydrometer method FDA called unsuitable. FDA also found no stability data supporting the labeled 24-month expiry.

What FDA found

  1. The firm did not test each finished OTC drug batch for identity and strength of active ingredients before release.

    21 CFR 211.165(a)
  2. The firm used a hydrometer method that FDA said was unsuitable for testing its finished drug products.

    21 CFR 211.160(b)
  3. The firm did not perform at least one identity test on each incoming component and relied only on supplier test reports.

    21 CFR 211.84(d)(1)
  4. The firm did not show stability testing that supports the labeled 24-month expiry for its drug products.

    21 CFR 211.166(a)

What FDA wants

FDA tells the firm to respond in writing within 15 working days with corrective actions, including finished-product test specifications and retain-sample testing, component identity testing and supplier-report validation, and a stability-program corrective action plan. FDA also recommends a consultant qualified in current good manufacturing practice (CGMP).

Who should pay attention

  • US brands and importers sourcing OTC drugs from this manufacturer
  • distributors and retailers selling OTC drug products made by this firm
  • suppliers of raw drug components to this facility

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk